Endocrine Abstracts

Background: Cardiovascular events are the major cause of mortality among patients with type 2 diabetes mellitus (DM2). Menopause in women additionally increases cardiovascular risk. Despite myocardial infarction (MI) treatment approach in diabetic patients is not specific, some glucose-lowering drugs could have cardioprotective properties. In general, most glucagon-like peptide-1 receptor agonists (GLP-1Ra) and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have cardiova...

Background and aimsAlthough bone fracture risk increases in DM, bone mineral density does not completely reflect bone fragility. It is important to explore other methods of osteoporotic fracture risk evaluation. Nowadays bone turnover markers (BTM) investigation is not widely used in clinical practice. On the other hand, the action of some glucose-lowering drugs on bone remodeling is not completely explored. The aim of this study was to investigate and t...

Background:Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having most prominent cardioprotective properties. Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have demonstrated an ability to decrease heart failure manifestations, cardiovascular death frequency not having a certain influence on MI occurrence. On ...